Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
EDX Medical Group PLC - Cambridge, England-based firm that develops digital diagnostic products and services to treat cancer, heart disease, and infectious diseases - Signs master services agreement with Royal Marsden NHS Foundation Trust. The agreement will see EDX supply services to Royal Marsden over a three-year period. EDX Medical Founder & Chief Scientific Officer Chris Evans comments: ‘I am delighted EDX Medical has now been appointed as a supplier of diagnostic solutions and services to help serve the needs of one of the world’s most eminent cancer hospitals.’
Current stock price: 12.75 pence
12-month change: up 24%
Copyright 2025 Alliance News Ltd. All Rights Reserved.